Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy of malignancies: current status.

F R Eilber, E C Holmes, D L Morton

    AJR. American Journal of Roentgenology
    |May 1, 1976
    PubMed
    Summary

    Nonspecific immunologic stimulants like BCG show promise in cancer immunotherapy by augmenting the immune response against tumors. This approach is most effective for minimal residual disease and requires combination therapy for larger tumor burdens.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer.

    Seminars in oncology·2001
    Same author

    Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma.

    CA: a cancer journal for clinicians·2001
    Same author

    Immunology of gangliosides.

    Indian journal of experimental biology·2001
    Same author

    Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2000

    Area of Science:

    • Immunology
    • Oncology
    • Cancer Research

    Background:

    • Human malignancies elicit an active immune response against tumor-associated antigens.
    • Nonspecific immunologic stimulants, such as Bacillus Calmette-Guérin (BCG), can augment this immune response.
    • Current immunotherapy strategies show variable efficacy depending on tumor burden and administration route.

    Purpose of the Study:

    • To evaluate the efficacy of nonspecific immunologic stimulants in cancer therapy.
    • To determine the optimal conditions for immunotherapy, particularly concerning tumor burden and combination treatments.
    • To explore potential improvements in immunotherapy by combining stimulants with tumor-associated antigens.

    Main Methods:

    • In vitro analyses of immune responses against cancer antigens.
    • In vivo studies using immunologic stimulants like BCG and C. parvum.
    • Preliminary clinical trials assessing systemic administration of immune stimulants.
    • Evaluation of immunotherapy in combination with irradiation or chemotherapy.

    Main Results:

    • Nonspecific immunologic stimulants demonstrate effectiveness in augmenting anti-tumor immune responses.
    • Intracutaneous administration of BCG is effective for localized disease, while systemic administration shows benefit in minimal residual disease.
    • Immunotherapy is minimally toxic and effective across a spectrum of cancers but less so for large tumor burdens.
    • Early trials with BCG for melanoma and C. parvum for oat cell carcinoma are encouraging.

    Conclusions:

    • Immunotherapy is a systemically active cancer treatment with minimal toxicity, most beneficial for minimal residual disease.
    • Combination therapy with irradiation or chemotherapy is necessary for cases with significant tumor burden.
    • Future improvements may involve combining nonspecific immunologic stimulants with tumor-associated antigens for enhanced efficacy in human neoplasms.

    Related Experiment Videos